RxDoctor Payments Data

Kisuk Cho, MD

Internal Medicine · Santa Clara, CANPI 1225122880

Payments from drug & device makers

$1,786in general payments, 2019–2025

Across 187 payments — averaging $9.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$776
  • Gilead$432
  • Amarin Pharma, Inc.$339
  • Aimmune Therapeutics, Inc.$60
  • GSK$58
  • AstraZeneca$50
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$1,63291%
  • Education$1539%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,786 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$479,948
Medicare patients
390
Services billed
6,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase118$228,892
ZenpepLipase/Protease/Amylase43$128,509
JanuviaSitagliptin Phosphate66$98,017
EliquisApixaban33$50,884
VemlidyTenofovir Alafenamide26$50,649
OzempicSemaglutide27$36,577
TradjentaLinagliptin24$31,282
Atorvastatin Calcium1,425$22,038
JardianceEmpagliflozin15$21,146
VascepaIcosapent Ethyl29$20,157
Ursodiol103$19,908
Entecavir26$12,854
Celecoxib55$12,647
Losartan Potassium658$10,062
Acarbose181$10,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$776$228,892118 claims
Aimmune Therapeutics, Inc.Zenpep$60$128,50943 claims
PfizerEliquis$16$50,88433 claims
GileadVemlidy$432$50,64926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Clara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →